Applications of Ziprasidone in Industrial Manufacturing

Ziprasidone is a pharmaceutical raw material primarily used in the synthesis of finished psychiatric medications. Our facility supplies high-purity Ziprasidone directly to regulated industries integrating advanced chemical synthesis, precision quality control, and strict documentation for compliance-driven sectors. Below, we detail major application areas based on distinct downstream manufacturing routes, regulatory requirements, and end product deliverables.

1. Formulation of Antipsychotic Oral Solid Dosage (OSD)

Pharmaceutical manufacturers utilize Ziprasidone as a key active pharmaceutical ingredient (API) in the production of oral solid forms, notably capsules and tablets for the treatment of schizophrenia and bipolar disorder. Production is conducted under stringent GMP guidance, involving precise API-excipient blending, wet or dry granulation, and tablet compression or capsule filling. Integration of this material demands consistency in particle size and polymorphic purity for batch-reproducible dissolution and bioavailability profiles, audited by periodic in-house and third-party analysis.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for APIs
• United States Pharmacopeia (USP) Monographs – Ziprasidone
• European Pharmacopoeia (Ph. Eur.) specifications
• FDA cGMP (21 CFR Parts 210 & 211)

Typical usage ratio

• API load ranges from 20 mg to 160 mg per unit, dependent on tablet strength and formulation requirements
• API typically comprises 2% - 8% of total tablet mass, adjustable for desired dosage

Downstream process integration

• Direct addition to pre-mix during granulation steps after QC release
• Blended with pharmaceutical excipients such as lactose, microcrystalline cellulose, magnesium stearate
• Quality assurance sampling pre- and post-blending
• Compression or encapsulation in controlled areas

Final product types

• Prescription tablets (various strengths, e.g., 20 mg, 40 mg, 60 mg, 80 mg, 100 mg)
• Hard gelatin capsules
• Branded and generic antipsychotic medications

2. Sterile Injectable Antipsychotic Production

Injectable drug manufacturers source our Ziprasidone for formulation into sterile aqueous solutions or lyophilized powders used for intramuscular administration, addressing acute agitation or non-oral compliance. The material undergoes purification, dissolution in sterile water-for-injection, potential pH adjustment, sterile filtration, and aseptic filling into vials. Throughout this process, manufacturers control for endotoxin levels, impurity limits, and particle count per GMP Annex 1 guidelines.

Industry compliance standards

• European Union GMP Annex 1 (Sterile Medicinal Products)
• USP <797> Compounding Sterile Preparations
• Chinese Pharmacopoeia (ChP) APIs and sterile process validation
• EMA/CHMP Quality Guidelines

Typical usage ratio

• Concentrations from 20 mg/ml to 40 mg/ml for single-dose injectable vials
• API content finalized by clinical monograph

Downstream process integration

• Dispersion in manufacturing vessel immediately prior to filtration
• Integration with sodium citrate or other solubilizing/stabilizing agents
• Sterile filtration and aseptic filling into vials under laminar flow
• Terminal sterilization or lyophilization as per formulation protocol

Final product types

• Single-dose sterile vials (e.g., 20 mg, 40 mg per vial)
• Lyophilized ziprasidone powder for reconstitution
• Hospital and institutional injectable drugs for acute psychiatric intervention

3. Research-Grade Reference Standards Production

Specialty laboratories and pharmaceutical R&D centers source reference-grade Ziprasidone material for use in method validation, stability assessment, and bioanalytical assay development. We produce analytical-grade lots with comprehensive traceability, enabling downstream customers to establish HPLC, LC-MS, or dissolution tests under regulated laboratory settings. Documentation includes full certificate of analysis (COA), impurity profile, and shelf life stability data as demanded by international research compliance frameworks.

Industry compliance standards

• ISO 17034 Accreditation for Reference Material Producers
• ISO/IEC 17025 Laboratory Competence for Testing and Calibration
• USP General Chapters <1225> and <1226> (Validation of Compendial Procedures, Verification of Compendial Procedures)
• GLP (Good Laboratory Practice) guidelines

Typical usage ratio

• Assay calibrators typically use 1–10 mg/ml solutions for HPLC/LCMS
• Usage per test batch based on method development protocols and validation plan

Downstream process integration

• Direct dissolution into defined solvents for calibration curves
• Preparation of spike/recovery samples to establish analytical method reliability
• Use in forced degradation studies for impurity profiling
• Documentation included in regulatory submission dossiers

Final product types

• HPLC/LC-MS analytical standards
• System suitability test sets
• Analytical control samples for GMP lab quality assurance

4. GMP Bulk API Supply for Blister Packaging Facilities

Contract blisters and private label manufacturers purchase GMP bulk batches to integrate into secondary packaging lines. Bulk supply enables high-volume production runs, where each batch is validated for identity, assay, and microbiological attributes prior to downstream transformation. These facilities require bulk supply packaged with tamper-evident seals, detailed batch documentation, and continuous audit traceability as part of branded and generic logistics chain integrity.

Industry compliance standards

• ICH Q3A/B for impurities in new drug substances
• ISO 9001:2015 Quality Management Systems
• Good Distribution Practice (GDP) for pharmaceuticals
• Annex 16 (Certification by a Qualified Person and Batch Release, EU GMP)

Typical usage ratio

• Bulk batch shipment of 5 kg to 50 kg per production lot
• Unit dose strengths maintained as per market authorization files

Downstream process integration

• Dispensing directly into OSD or capsule blending hopper after verification
• Incorporation into automated blister pack lines for final consumer packaging
• Quality reports accompanying each shipment, reviewed before release
• Traceability checks for cross-batch audit compliance

Final product types

• Blister packed antipsychotic tablets and capsules
• Multi-dose hospital pack configurations
• Retail-ready and hospital-use oral dosage products